Raymone Pajarillo
A5083380786- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Cancer Immunotherapy and Biomarkers
- Viral Infectious Diseases and Gene Expression in Insects
- Immunotherapy and Immune Responses
- CRISPR and Genetic Engineering
- Integrated Circuits and Semiconductor Failure Analysis
- Lymphoma Diagnosis and Treatment
- Biosimilars and Bioanalytical Methods
- RNA Interference and Gene Delivery
- Virus-based gene therapy research
- Childhood Cancer Survivors' Quality of Life
- Advancements in Semiconductor Devices and Circuit Design
- Monoclonal and Polyclonal Antibodies Research
- Nanofabrication and Lithography Techniques
- Gut microbiota and health
- Pancreatic function and diabetes
- Diet, Metabolism, and Disease
- Diet and metabolism studies
- T-cell and B-cell Immunology
- Nanowire Synthesis and Applications
- Single-cell and spatial transcriptomics
- Chronic Lymphocytic Leukemia Research
- Neutropenia and Cancer Infections
- Hematopoietic Stem Cell Transplantation
Hospital of the University of Pennsylvania
2020-2025
University of Pennsylvania
2020-2024
UPMC Hillman Cancer Center
2023-2024
Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy (CART19) occurs in 10% 20% of patients with acute lymphoblastic leukemia (ALL); however, the mechanisms this remain elusive. Using a genome-wide loss-of-function screen, we identified that impaired death signaling ALL led rapidly progressive disease despite CART19 treatment. This was mediated by an inherent cytotoxicity permitted persistence and subsequently magnified induction CAR functional impairment. These...
Abstract Chimeric antigen receptor T-cell (CART) immunotherapy led to unprecedented responses in patients with refractory/relapsed B-cell non-Hodgkin lymphoma (NHL); nevertheless, two thirds of experience treatment failure. Resistance apoptosis is a key feature cancer cells, and it associated In 87 NHL treated anti-CD19 CART, we found that chromosomal alteration 2 (BCL-2), critical antiapoptotic regulator, cells was reduced survival. Therefore, combined CART19 the FDA-approved BCL-2...
Several studies have shown the influence of commensal microbes on T cell function, specifically in setting checkpoint immunotherapy for cancer. In this study, we investigated how vancomycin-induced gut microbiota dysbiosis affects chimeric antigen receptor (CAR) using multiple preclinical models as well clinical correlates. two murine tumor models, hematopoietic CD19+-A20 lymphoma and CD19+-B16 melanoma, mice receiving vancomycin combination with CD19-directed CAR (CART-19) therapy displayed...
BackgroundAdministration of anti-CD19 chimeric antigen receptor T-cell (CART19) immunotherapy for large B-cell lymphomas (LBCLs), a subset non-Hodgkin lymphoma (NHL), involves high costs and access to specialized tertiary care centers. We investigated whether minority health populations (MHPs) have equal CART19 their outcomes are similar those non-MHPs. MethodsWe analyzed the prevalence clinical patients treated with commercial at two geographically socioeconomically different institutions:...
Most patients treated with US Food and Drug Administration (FDA)–approved chimeric antigen receptor (CAR) T cells eventually experience disease progression. Furthermore, CAR have not been curative against solid cancers several hematological malignancies such as cell lymphomas, which very poor prognoses. One of the main barriers to clinical success adoptive immunotherapies is dysfunction lack expansion and/or persistence after infusion. In this study, we found that CD5 inhibits activation...
Lymphodepletion (LD) is an integral component of chimeric antigen receptor T-cell (CART) immunotherapies. In this study, we compared the safety and efficacy bendamustine (Benda) to standard fludarabine/cyclophosphamide (Flu/Cy) LD before CD19-directed, CD28-costimulated CART axicabtagene ciloleucel (axi-cel) for patients with large B-cell lymphoma (LBCL) follicular (FL). We analyzed 59 diagnosed LBCL (n = 48) FL 11) consecutively treated axi-cel at University Pennsylvania. also serum samples...
Abstract Background Commercial anti-CD19 chimeric antigen receptor T-cell therapies (CART19) are efficacious against advanced B-cell non-Hodgkin lymphoma (NHL); however, most patients ultimately relapse. Several mechanisms contribute to this failure, including CD19-negative escape and CAR T dysfunction. All four commercial CART19 products utilize the FMC63 single-chain variable fragment (scFv) specific a CD19 membrane-distal epitope characterized by slow association (on) dissociation (off)...
Abstract Patients with B-cell lymphomas have altered cellular components of vaccine responses due to malignancy and therapy, the optimal timing vaccination relative therapy remains unknown. Severe acute respiratory syndrome coronavirus 2 vaccines created an opportunity for new insights in because patients were challenged a novel antigen across multiple phases treatment. We studied serologic messenger RNA response retrospective prospective cohorts lymphoma chronic lymphocytic leukemia, paired...
Abstract Patients with multiple myeloma (MM) treated B-cell maturation antigen (BCMA)-specific chimeric receptor (CAR) T cells usually relapse BCMA+ disease, indicative of CAR T-cell suppression. CD200 is an immune checkpoint that overexpressed on aberrant plasma (aPCs) in MM and independent negative prognostic factor for survival. However, not present cell lines, a potential limitation current preclinical models. We engineered lines to express at levels equivalent those found aPCs show...
Introduction: Lymphodepletion (LD) is a key component of anti-CD19 chimeric antigen receptor T cell (CART19) immunotherapy, establishing the proper environment and cytokine milieu before CART infusion. We previously demonstrated that Bendamustine (Benda) LD as effective standard fludarabine cyclophosphamide (Flu/Cy) 4-1BB-costimulated tisagenlecleucel, but has reduced cytokine-release syndrome (CRS), neurotoxicity (ICANS), hematological toxicities. However, it remains unknown whether Benda...